Date | Price Target | Rating | Analyst |
---|---|---|---|
3/7/2024 | $5.00 | Hold → Buy | The Benchmark Company |
11/20/2023 | Underweight | JP Morgan | |
8/29/2023 | Buy → Hold | The Benchmark Company | |
4/10/2023 | $22.00 | Hold → Buy | The Benchmark Company |
3/17/2023 | $23.00 → $9.00 | Neutral → Underweight | JP Morgan |
11/10/2022 | Buy → Hold | The Benchmark Company | |
4/29/2022 | Overweight → Neutral | Cantor Fitzgerald | |
3/10/2022 | $37.00 → $40.00 | Equal-Weight | Wells Fargo |
GAITHERSBURG, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today highlights several recent advancements in improving its financial health, marked by robust cash generation and meaningful debt repayment. As set forth in its operational plan to transform the company over the next several years, Emergent is diligently executing its strategy to enhance operational efficiency, streamline costs, and generate cash to increase profitability and reduce the company's overall debt. This disciplined approach has enhanced Emergent's financial position, as well as enabling a customer focused, leaner and more flexible organization, and enriching its opportunities to pursue
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it has received more than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS), to deliver millions of doses of four medical countermeasures (MCMs). These contract modifications will help ensure continued supply/stockpiling of critical MCMs to address biological threats and emergencies against anthrax, smallpox and botulism. The four awards include: A contract modification valued at $30.0 million to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) this y
GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. ("Bora", TWSE: 6472), a leading international pharmaceutical services company, for a total value of approximately $30 million. The Camden site, which is part of Emergent's Contract Development and Manufacturing Organization (CDMO), has clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services. Alongside the facility, approximately 350 curre
Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard of care for opioid overdose reversal in a community settingNew topline survey findings reinforce the need for continued education on naloxone GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- In recognition of National Naloxone Awareness Day, Emergent BioSolutions Inc. (NYSE:EBS) is highlighting its ongoing efforts to combat the opioid epidemic in the U.S., including topline results from its new general population awareness survey on consumers' understanding of opioid-related accidental overdose and fentanyl. The results show that there is a high level of awareness that fentanyl is an opio
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
SC 13G - Emergent BioSolutions Inc. (0001367644) (Subject)
GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. ("Bora", TWSE: 6472), a leading international pharmaceutical services company, for a total value of approximately $30 million. The Camden site, which is part of Emergent's Contract Development and Manufacturing Organization (CDMO), has clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services. Alongside the facility, approximately 350 curre
WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p
Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai
GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent's 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. "Neal and Don bring unique and extensive expertise to Emergent as the company defines its future in this post-pandemic environment," said Emergent Chairman Dr. Zsolt Harsanyi, Ph.D. "Maintaining our focus on our mission of protecting and enhancing life, these industry veterans add v
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $5.00
JP Morgan resumed coverage of Emergent BioSolutions with a rating of Underweight
The Benchmark Company downgraded Emergent BioSolutions from Buy to Hold
The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $22.00
First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 millionUpdates FY 2024 guidance GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March 31, 2024. "We delivered a strong quarter with growth across all our key products," said Joe Papa, President and CEO at Emergent. "We also took significant actions to improve our debt position, reduce operating expenses and strengthen our financial flexibility. Emergent's transformation will not happen overnight. The actions we
Proactive changes aim to ensure long-term sustainability and growth, optimize operations, streamline processes, and allocate resources more efficientlyReorganization will align with evolving business goals, strategic priorities and new operational planOverall efforts expected to deliver annual cost savings of approximately $80 million GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced the next phase of its new operational plan that consolidates operations, closes several manufacturing facilities, and restructures its enterprise workforce to improve the performance and profitability of its business. Emergent will continue to focus on its c
GAITHERSBURG, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced that it has entered into a "Consent, Waiver and Seventh Amendment" to its existing credit facility. "In light of this amendment, Emergent now has an extended runway to execute on our go-forward business plan to stabilize our financial position," stated Joe Papa, president and CEO of Emergent. "Our bank group continues to work with our management team in a constructive fashion, evidenced by this positive development." On May 1, 2024, Emergent will report its first quarter 2024 financial results via conference call, as well highlight key business updates, Q1 2024 financial review, and FY 2
GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024. Conference Call InformationParticipants can access the conference call live via webcast. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registr
American Express Company (NYSE:AXP) will release its second-quarter financial results, before the opening bell on Friday, July 19. Analysts expect the New York-based company to report quarterly earnings at $3.25 per share, up from $2.89 per share in the year-ago period. American Express will post revenue of $16.59 billion, compared to $15.05 billion a year earlier, according to data from Benzinga Pro. On July 16, Compass Point analyst David Rochester initiated coverage on American Express with a Neutral rating and announced a price target of $260. With the recent buzz around American Express, some investors may be eyeing potential gains from the company's dividends, too. As of now,
Johnson & Johnson (NYSE:JNJ) will release its second-quarter financial results, before the opening bell on Wednesday, July 17. Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.70 per share, up from $2.56 per share in the year-ago period. Johnson & Johnson is expected to post revenue of $22.29 billion, compared to $25.53 billion a year earlier, according to data from Benzinga Pro. Emergent BioSolutions Inc (NYSE:EBS), through its subsidiary Emergent Manufacturing Operations Baltimore, recently reached a settlement with Janssen Pharmaceuticals, Inc., a branch of Johnson & Johnson, resolving disputes related to the manufacturing of Johnson & J
U.S. pharma giant Johnson & Johnson (NYSE:JNJ) will report its second-quarter 2024 earnings on Wednesday, July 17. As per data from Benzinga Pro, analysts estimate sales of $22.29 billion and adjusted EPS of $2.71. Based on a quarterly review of events, management’s insights on product and market dynamics, and an analysis of prescription trends, a Goldman Sachs analyst says Johnson & Johnson is on track to meet its fiscal year 2024 guidance. For the second quarter, the analyst considers both their and the market’s revenue and EPS expectations reasonable. Related: Johnson & Johnson’s Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients. Goldman Sach
Emergent BioSolutions Inc (NYSE:EBS), through its subsidiary Emergent Manufacturing Operations Baltimore, has reached a settlement with Janssen Pharmaceuticals, Inc., a branch of Johnson & Johnson (NYSE:JNJ), resolving disputes related to the manufacturing of Johnson & Johnson’s investigational COVID-19 vaccine. This settlement ends claims arising from their manufacturing services agreement and related arbitration. Related: Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday? Under the confidential Settlement Agreement and Release terms, Janssen will pay Emergent BioSolutions $50 million. The settlement includes broad releases for all involved parties. This